Management of Retinopathy of Prematurity (ROP): 80 Years of Vision

ONLINECMECNERxNEO Grand Rounds
Management of Retinopathy of Prematurity (ROP): 80 Years of Vision Banner

Instructions

Date & Location
Friday, September 4, 2020, 8:00 AM - Sunday, September 3, 2023, 11:59 PM, Online

Credits
AMA PRA Category 1 Credits™ (1.00 hours), ANCC Nursing Contact Hour(s) (1.00 hours), Non-Physician (Attendance) (1.00 hours), Pharmacotherapeutics (1.00 hours)

Overview
Retinopathy of Prematurity is the leading cause of childhood blindness worldwide, but with appropriate treatment techniques, sight limiting outcomes can be largely avoided. Current standards for the treatment of ROP in the US and around the world are not standardized, leading to blindness continuing to occur. This presentation presents a model to safely treat and follow ROP infants, obviating blindness due to retinal pathology.

ACCME Objectives
  1. Discuss the current standard of care for the treatment of retinopathy of prematurity.
  2. Identify the safe application of anti–vascular endothelial growth factor (anti-VEGF) medication to the infant with retinopathy of prematurity.
  3. Illustrate the importance of careful and diligent follow up through the completion of retinal vascularization.

ANCC Learning Outcomes
  1. Discuss the current standard of care for the treatment of retinopathy of prematurity.
  2. Identify the safe application of anti–vascular endothelial growth factor (anti-VEGF) medication to the infant with retinopathy of prematurity.
  3. Illustrate the importance of careful and diligent follow up through the completion of retinal vascularization.

Accreditation

The MEDNAX Center for Research, Education, Quality and Safety is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The MEDNAX Center for Research, Education, Quality and Safety designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The MEDNAX Center for Research, Education, Quality and Safety is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. (#PO258)

The MEDNAX Center for Research, Education, Quality and Safety designates this Enduring Material for a maximum of 1.00 nursing contact hour(s). Participants should claim only the credit commensurate with the extent of their participation in the activity.

The MEDNAX Center for Research, Education, Quality and Safety designates this Enduring Material for a maximum of 1.00 pharmacotherapeutics contact hour(s).